NCT05229432 Study of Gastric Motility in Eosinophilic Gastritis
| NCT ID | NCT05229432 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Children's Hospital Medical Center, Cincinnati |
| Condition | Eosinophilic Gastritis |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2023-01-25 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2023-01-25 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Purpose: The study is a cross-sectional observational study designed to determine if eosinophilic gastritis (EG) results in gastric motility impairment. Hypothesis: Gastric dysfunction occurs in the natural history of EG but is underdiagnosed due, in part, to contraindications to the use of the standard meals used in gastric emptying studies.
Eligibility Criteria
Inclusion Criteria: * Eosinophilic gastritis (EG) defined as at least one endoscopy with histopathologic evidence of ≥ 30 eosinophils in 5 or more high powered fields (hpf's) with associated symptoms of EG. * Patient reported symptoms starting at least one year or more prior to screening consistent with a diagnosis of EG: nausea, vomiting, early satiety, abdominal pain/bloating, regurgitation, diarrhea. * Symptoms suggestive of a possible gastric motility disorder during the 60 days prior to screening including: nausea, vomiting, early satiety, post-prandial feeling of fullness or bloating. * Tolerance and willingness to consume the oatmeal meal in this study. Exclusion Criteria: * Diagnosis of eosinophilic enteritis. * Inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis). * Known disorders associated with eosinophilic gastrointestinal (GI) diseases (e.g., D 816 V Kit+ systemic mastocytosis, Marfan syndrome or Loey's Dietz Syndrome). * Known inflammatory or autoimmu
Frequently Asked Questions
Who can join the NCT05229432 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 59 Years, studying Eosinophilic Gastritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05229432 currently recruiting?
Yes, NCT05229432 is actively recruiting participants. Visit ClinicalTrials.gov or contact Children's Hospital Medical Center, Cincinnati to inquire about joining.
Where is the NCT05229432 trial being conducted?
This trial is being conducted at Chicago, United States, Bethesda, United States, Salt Lake City, United States.
Who is sponsoring the NCT05229432 clinical trial?
NCT05229432 is sponsored by Children's Hospital Medical Center, Cincinnati. The trial plans to enroll 30 participants.